Monday, January 05, 2026




In Detail Full day, Monday, January 05, 2026, Timezone: America/Chicago


RFK Jr.'s CDC whacks 6 vaccines from childhood recommendation list after opaque monthlong review / Fierce

fiercehealthcare - The Centers for Disease Control and Prevention (CDC) has upended the immunization schedule for children in the United States, eliminating six of the 17 vaccines that were previously recommended to protect them from disease.

#healthcare #publichealth #governmentpolicy #cdc #vaccinesafety


Monday, January 5, 2026, 5:22 pm / permalink 17518 / 28 stories in 2 months


UK starts ban on junk food ads on daytime TV and online / Medical Express

medicalxpress - New regulations come into force Monday in Britain banning daytime TV and online adverts for so-called junk foods, in what the government calls a "world-leading action" to tackle childhood obesity.

#obesity #healthcare #publichealth #governmentpolicy


Monday, January 5, 2026, 4:22 am / permalink 17491 / 3 stories in 2 months


FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints

Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months


StackHealth Time Machine




Outgoing Stories


HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours

Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours

FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours

HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours

Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours

Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours

Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours

AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours


More StackHealth


Bluesky:



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.